お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙:悪性胸水:パイプライン製品の分析
市場調査レポート
商品コード
484633

悪性胸水:パイプライン製品の分析

Malignant Pleural Effusion - Pipeline Review, H2 2020

出版日: | 発行: Global Markets Direct | ページ情報: 英文 50 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=110.15円
悪性胸水:パイプライン製品の分析
出版日: 2020年09月30日
発行: Global Markets Direct
ページ情報: 英文 50 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

悪性胸水は、癌によって、異常な量の流体が、肺の外側に沿って並んでいる組織(肋膜)の薄い層と胸腔の壁の間で集まっている状態です。肺癌、乳癌、リンパ腫および白血病によって、大部分の悪性胸水が起きます。

当レポートでは、世界各国での悪性胸水治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

イントロダクション

  • 調査範囲

悪性胸水;概要

悪性胸水 - 治療薬の開発

  • パイプライン製品 概要
  • パイプライン製品:企業別
  • 企業で開発中の製品

治療薬の評価

  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

治療薬開発に従事している企業

  • Advantagene Inc
  • Biogen Inc
  • Genelux Corp
  • Shenzen SiBiono GeneTech Co Ltd

薬剤プロファイル

休止中のプロジェクト

製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

図表

List of Tables

List of Tables

  • Number of Products under Development for Malignant Pleural Effusion, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Products under Development by Companies, H2 2020
  • Number of Products by Stage and Target, H2 2020
  • Number of Products by Stage and Mechanism of Action, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Malignant Pleural Effusion - Pipeline by Amgen Inc, H2 2020
  • Malignant Pleural Effusion - Pipeline by Biogen Inc, H2 2020
  • Malignant Pleural Effusion - Pipeline by BioSyngen Pte Ltd, H2 2020
  • Malignant Pleural Effusion - Pipeline by Clover Biopharmaceuticals, H2 2020
  • Malignant Pleural Effusion - Pipeline by Genelux Corp, H2 2020
  • Malignant Pleural Effusion - Pipeline by Gongwin Biopharm Holdings Co Ltd, H2 2020
  • Malignant Pleural Effusion - Pipeline by Hubei Soundny Bio-Tech Co Ltd, H2 2020
  • Malignant Pleural Effusion - Pipeline by Lipac Oncology LLC, H2 2020
  • Malignant Pleural Effusion - Dormant Projects, H2 2020

List of Figures

List of Figures

  • Number of Products under Development for Malignant Pleural Effusion, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products by Targets, H2 2020
  • Number of Products by Stage and Targets, H2 2020
  • Number of Products by Mechanism of Actions, H2 2020
  • Number of Products by Stage and Mechanism of Actions, H2 2020
  • Number of Products by Routes of Administration, H2 2020
  • Number of Products by Stage and Routes of Administration, H2 2020
  • Number of Products by Molecule Types, H2 2020
  • Number of Products by Stage and Molecule Types, H2 2020
目次
Product Code: GMDHC12531IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Malignant Pleural Effusion - Pipeline Review, H2 2020, provides an overview of the Malignant Pleural Effusion (Respiratory) pipeline landscape.

Malignant pleural effusion is a condition in which cancer causes an abnormal amount of fluid to collect between the thin layers of tissue (pleura) lining the outside of the lung and the wall of the chest cavity. Lung cancer, breast cancer, lymphoma, and leukemia cause most malignant pleural effusions.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Malignant Pleural Effusion - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Malignant Pleural Effusion (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Malignant Pleural Effusion (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Malignant Pleural Effusion and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 2, 4 and 2 respectively.

Malignant Pleural Effusion (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Malignant Pleural Effusion (Respiratory).
  • The pipeline guide reviews pipeline therapeutics for Malignant Pleural Effusion (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Malignant Pleural Effusion (Respiratory) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Malignant Pleural Effusion (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Malignant Pleural Effusion (Respiratory)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Malignant Pleural Effusion (Respiratory).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Malignant Pleural Effusion (Respiratory) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Malignant Pleural Effusion - Overview
  • Malignant Pleural Effusion - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Products under Development by Companies
  • Malignant Pleural Effusion - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Malignant Pleural Effusion - Companies Involved in Therapeutics Development
  • Amgen Inc
  • Biogen Inc
  • BioSyngen Pte Ltd
  • Clover Biopharmaceuticals
  • Genelux Corp
  • Gongwin Biopharm Holdings Co Ltd
  • Hubei Soundny Bio-Tech Co Ltd
  • Lipac Oncology LLC
  • Malignant Pleural Effusion - Drug Profiles
  • BG-00001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BSG-001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • methotrexate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • olvimulogene nanivacirepvec - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • paclitaxel - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PTS-500 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SCB-313 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • talimogene laherparepvec - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Malignant Pleural Effusion - Dormant Projects
  • Malignant Pleural Effusion - Product Development Milestones
  • Featured News & Press Releases
  • Jan 10, 2020: Clover Biopharmaceuticals doses first patient in phase I study of SCB-313 in China for Malignant Pleural Effusions (MPE)
  • Nov 21, 2019: Clover Biopharmaceuticals doses first patient in Phase I study of SCB-313 in Australia for Malignant Pleural Effusions (MPE)
  • Sep 29, 2019: Clover Biopharmaceuticals doses first patient in phase I study of SCB-313 in China for Malignant Ascites
  • May 12, 2015: Genelux to Present Posters Supporting Lead Oncolytic Viral Therapy GL-ONC1 at ASCO Annual Meeting 2015
  • Jun 15, 2013: Genelux Presents Abstracts at the 7th International Meeting on Replicating Oncolytic Virus Therapeutics in Quebec
  • May 30, 2013: Genelux To Present Abstracts For Clinical Trials Of Oncolytic Viral Therapy GL-ONC1 At 2013 ASCO Annual Meeting
  • Feb 06, 2013: Genelux Announces Treatment Of First Patient In Phase I Trial With GL-ONC1 At Memorial Sloan Kettering Cancer Center
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.